[go: up one dir, main page]

MX2011012356A - Compuesto anticanceroso y composicion farmaceutica que lo contiene. - Google Patents

Compuesto anticanceroso y composicion farmaceutica que lo contiene.

Info

Publication number
MX2011012356A
MX2011012356A MX2011012356A MX2011012356A MX2011012356A MX 2011012356 A MX2011012356 A MX 2011012356A MX 2011012356 A MX2011012356 A MX 2011012356A MX 2011012356 A MX2011012356 A MX 2011012356A MX 2011012356 A MX2011012356 A MX 2011012356A
Authority
MX
Mexico
Prior art keywords
same
pharmaceutical composition
compound
composition containing
anticancer compound
Prior art date
Application number
MX2011012356A
Other languages
English (en)
Inventor
Francois Clerc
Cecile Combeau
Jean-Christophe Carry
Laurent Schio
Michel Cheve
Sylvie Gontier
Alain Krick
Sylvette Lachaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2011012356A publication Critical patent/MX2011012356A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al compuesto de fórmula (I) más particularmente eh su forma levógira (la), particularmente la que presenta el poder rotatorio [a]D = -38.6 +- 0.7 a una concentración de 0.698 mg/mI en metanol. El compuesto puede existir en forma de base o de una sal de adición a un ácido, particularmente un ácido farmacéuticamente aceptable. Este compuesto es un inhibidor selectivo de las quinasas Aurora A y B. Puede utilizarse como agente anticanceroso.
MX2011012356A 2009-05-18 2010-05-17 Compuesto anticanceroso y composicion farmaceutica que lo contiene. MX2011012356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant
PCT/FR2010/050948 WO2010133794A1 (fr) 2009-05-18 2010-05-17 Compose anticancéreux et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
MX2011012356A true MX2011012356A (es) 2011-12-14

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012356A MX2011012356A (es) 2009-05-18 2010-05-17 Compuesto anticanceroso y composicion farmaceutica que lo contiene.

Country Status (34)

Country Link
US (2) US9073917B2 (es)
EP (1) EP2432766B1 (es)
JP (1) JP5656981B2 (es)
KR (1) KR20120032483A (es)
CN (1) CN102459193B (es)
AR (1) AR076686A1 (es)
AU (1) AU2010251013B2 (es)
BR (1) BRPI1012201A2 (es)
CA (1) CA2762233C (es)
CL (1) CL2011002930A1 (es)
CO (1) CO6400138A2 (es)
CY (1) CY1114850T1 (es)
DK (1) DK2432766T3 (es)
EA (1) EA021084B1 (es)
ES (1) ES2430989T3 (es)
FR (1) FR2945535B1 (es)
HR (1) HRP20130959T1 (es)
IL (1) IL216361A0 (es)
JO (1) JO2852B1 (es)
MA (1) MA33356B1 (es)
ME (1) ME01542B (es)
MX (1) MX2011012356A (es)
MY (1) MY152995A (es)
NZ (1) NZ596464A (es)
PL (1) PL2432766T3 (es)
PT (1) PT2432766E (es)
RS (1) RS53002B (es)
SG (1) SG176169A1 (es)
SI (1) SI2432766T1 (es)
SM (1) SMT201400005B (es)
TW (1) TWI441822B (es)
UY (1) UY32644A (es)
WO (1) WO2010133794A1 (es)
ZA (1) ZA201108447B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
WO2014059383A1 (en) 2012-10-12 2014-04-17 The Broad Institute, Inc. Gsk3 inhibitors and methods of use thereof
CN106795118B (zh) 2014-07-01 2019-10-08 武田药品工业株式会社 杂环化合物和它们作为类视黄醇相关的孤儿受体(ror)gamma-t抑制剂的用途
EP3606528B1 (en) 2017-04-05 2023-10-18 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036422A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
WO2002062795A2 (en) 2001-02-02 2002-08-15 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds and pharmaceutical use thereof
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
RU2006100484A (ru) * 2003-06-13 2006-06-10 Центарис ГмбХ, Германи (DE) Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках
SI1746097T1 (sl) 2005-07-20 2010-05-31 Aventis Pharma Sa dihidropiridin kondenzirani heterocikli postopek za njihovo pripravo njihova uporaba in sestavki ki jih vsebujejo
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
TW201100418A (en) 2011-01-01
EA021084B1 (ru) 2015-04-30
BRPI1012201A2 (pt) 2016-04-05
DK2432766T3 (da) 2013-10-28
CL2011002930A1 (es) 2012-06-29
AR076686A1 (es) 2011-06-29
HRP20130959T1 (hr) 2013-11-22
US9221817B2 (en) 2015-12-29
JP2012527436A (ja) 2012-11-08
FR2945535A1 (fr) 2010-11-19
JP5656981B2 (ja) 2015-01-21
AU2010251013A1 (en) 2011-12-08
CN102459193A (zh) 2012-05-16
IL216361A0 (en) 2012-01-31
EP2432766A1 (fr) 2012-03-28
EP2432766B1 (fr) 2013-07-17
EA201171429A1 (ru) 2012-05-30
RS53002B (en) 2014-04-30
NZ596464A (en) 2014-01-31
HK1167388A1 (en) 2012-11-30
WO2010133794A1 (fr) 2010-11-25
US20150266877A1 (en) 2015-09-24
SMT201400005B (it) 2014-03-07
ES2430989T3 (es) 2013-11-22
ME01542B (me) 2014-04-20
SG176169A1 (en) 2011-12-29
AU2010251013B2 (en) 2015-08-20
SI2432766T1 (sl) 2013-11-29
MY152995A (en) 2014-12-31
PT2432766E (pt) 2013-10-23
US20120220621A1 (en) 2012-08-30
JO2852B1 (en) 2015-03-15
US9073917B2 (en) 2015-07-07
CN102459193B (zh) 2014-08-27
TWI441822B (zh) 2014-06-21
ZA201108447B (en) 2013-01-30
KR20120032483A (ko) 2012-04-05
MA33356B1 (fr) 2012-06-01
CY1114850T1 (el) 2016-12-14
CO6400138A2 (es) 2012-03-15
UY32644A (es) 2010-12-31
FR2945535B1 (fr) 2011-06-10
CA2762233A1 (fr) 2010-11-25
CA2762233C (fr) 2017-11-28
PL2432766T3 (pl) 2013-12-31

Similar Documents

Publication Publication Date Title
MX2011012356A (es) Compuesto anticanceroso y composicion farmaceutica que lo contiene.
UA94052C2 (uk) Похідні піридазину
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
TW200608972A (en) Aryl-pyridine derivatives
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
IN2012DN03337A (es)
GEP20125459B (en) Compounds for inhibiting mitotic progression
TW200612958A (en) Substituted imidazole derivatives
MX2010005824A (es) Derivados de aminotiazol.
MX2011013884A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200740764A (en) Pyrazolone derivatives
PL1753723T3 (pl) Podstawione pochodne chinoliny jako inhibitory kinezyn mitotycznych
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
TR201907729T4 (tr) Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
IL191670A0 (en) Compounds for the inhibition of apoptosis
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TH135249A (th) สารประกอบตัวยับยั้งออโรราต้านมะเร็งและองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว, กระบวนการและอินเทอร์มิเดียทสำหรับการเตรียมสารเหล่านั้น
MX2007008281A (es) Preparacion de sales farmaceuticas de compuestos de piperazina.

Legal Events

Date Code Title Description
FG Grant or registration